Importantly, in PR-positive breast cancer patients who received local therapy followed by adjuvant tamoxifen, high PRA:PRB ratios predicted shorter disease-free survival, indicating resistance to tamoxifen [7]. This evidence concerns the gene RB1 and breast carcinoma.